US4414212A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treatment of pre-menstrual syndrome
Assignee: NAYLOR PAMELA HILDA
•
Filing: 1982-03-02
•
Granted: 1983-11-08
•
Expires: 2002-03-02
Abstract
Abstract This invention relates to a method of treatment and/or prophylaxis of pre-menstrual syndrome comprising the administration of a therapeutically or prophylactically effective dosage of at least one of ascorbic acid, EDTA, glutathione, and a compound of Formula I ##STR1## wherein X is a physiologically acceptable anion, and bioprecursors thereof, to a patient suffering from pre-menstrual syndrome.
Inventors
- 👤 Graham J. Naylor
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 19:02
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/54; A61K31/185; A61K31/19; A61K31/195; A61K31/335; A61K31/365; A61K31/375; A61K38/00; A61K38/04; A61K38/06; A61K38/063
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
73 words
A method of treatment of pre-menstrual syndrome in a female patient suffering from pre-menstrual syndrome, said method comprising the step of administering to said patient a therapeutically effective dosage of at least one compound selected from the group consisting of ascorbic acid, physiologically acceptable salts and esters thereof, EDTA, glutathione, physiologically acceptable salts and esters thereof, and a compound of Formula I ##STR3## wherein X is a physiologically acceptable anion, and bioprecursors thereof.
Claim 2
Independent Claim
73 words
A method of treatment of pre-menstrual syndrome in a female patient suffering from pre-menstrual syndrome, said method comprising the step of administering to said patient a therapeutically effective dosage of at least one compound selected from the group consisting of ascorbic acid, physiologically acceptable salts and esters thereof, EDTA, glutathione, physiologically acceptable salts and esters thereof, and a compound of Formula I ##STR3## wherein X is a physiologically acceptable anion, and bioprecursors thereof.
Claim 3
Dependent Claim
12 words
A method according to claim 1 wherein X is a halide anion.
Claim 4
Dependent Claim
12 words
A method according to claim 2 wherein the compound is methylene blue.
Claim 5
Dependent Claim
29 words
A method according to claim 3 wherein methylene blue is administered at a dosage rate of from 0.2 to 8 mg per kg bodyweight of the patient per day.
Claim 6
Independent Claim
75 words
A method of prophylaxis of pre-menstrual syndrome in a female patient who has suffered from pre-menstrual syndrome, said method comprising the step of administering to said patient a prophylactically effective dosage of at least one compound selected from the group consisting of ascorbic acid, physiologically acceptable salts and esters thereof, EDTA, glutathione, physiologically acceptable salts and esters thereof, and a compound of Formula I ##STR4## wherein X is a physiologically acceptable anion, and bioprecursors thereof.
Claim 7
Independent Claim
75 words
A method of prophylaxis of pre-menstrual syndrome in a female patient who has suffered from pre-menstrual syndrome, said method comprising the step of administering to said patient a prophylactically effective dosage of at least one compound selected from the group consisting of ascorbic acid, physiologically acceptable salts and esters thereof, EDTA, glutathione, physiologically acceptable salts and esters thereof, and a compound of Formula I ##STR4## wherein X is a physiologically acceptable anion, and bioprecursors thereof.
Claim 8
Dependent Claim
12 words
A method according to claim 5 wherein X is a halide anion.
Claim 9
Dependent Claim
12 words
A method according to claim 6 wherein the compound is methylene blue.
Claim 10
Dependent Claim
29 words
A method according to claim 7 wherein methylene blue is administered at a dosage rate of from 0.2 to 8 mg per kg bodyweight of the patient per day.
Claim 11
Independent Claim
84 words
A method of treatment of pre-menstrual syndrome in a female patient suffering from pre-menstrual syndrome, said method comprising the step of administering to said patient a vanadate ion induced Na-K ATPase inhibition reversing effective dosage of a vanadate ion induced Na-K ATPase inhibition reversing agent selected from the group consisting of ascorbic acid, physiologically acceptable salts and esters thereof, EDTA, glutathione, physiologically acceptable salts and esters thereof, and a compound of Formula I ##STR5## wherein X is a physiological acceptable anion, and bioprecursors thereof.
Claim 12
Independent Claim
84 words
A method of treatment of pre-menstrual syndrome in a female patient suffering from pre-menstrual syndrome, said method comprising the step of administering to said patient a vanadate ion induced Na-K ATPase inhibition reversing effective dosage of a vanadate ion induced Na-K ATPase inhibition reversing agent selected from the group consisting of ascorbic acid, physiologically acceptable salts and esters thereof, EDTA, glutathione, physiologically acceptable salts and esters thereof, and a compound of Formula I ##STR5## wherein X is a physiological acceptable anion, and bioprecursors thereof.
Claim 13
Independent Claim
86 words
A method of prophylaxis of pre-menstrual syndrome in a female patient who has suffered from pre-menstrual syndrome, said method comprising the step of administering to said patient a vanadate ion induced Na-K ATPase inhibition reversing effective dosage of a vanadate ion induced Na-K ATPase inhibition reversing agent selected from the group consisting of ascorbic acid, physiologically acceptable salts and esters thereof, EDTA, glutathione, physiologically acceptable salts and esters thereof, and a compound of Formula I ##STR6## wherein X is a physiologically acceptable anion, and bioprecursors thereof.
Claim 14
Independent Claim
86 words
A method of prophylaxis of pre-menstrual syndrome in a female patient who has suffered from pre-menstrual syndrome, said method comprising the step of administering to said patient a vanadate ion induced Na-K ATPase inhibition reversing effective dosage of a vanadate ion induced Na-K ATPase inhibition reversing agent selected from the group consisting of ascorbic acid, physiologically acceptable salts and esters thereof, EDTA, glutathione, physiologically acceptable salts and esters thereof, and a compound of Formula I ##STR6## wherein X is a physiologically acceptable anion, and bioprecursors thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-11-07 | 1987-05-09 | 1987-11-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-11-07 | 1991-05-09 | 1991-11-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-11-07 | 1995-05-09 | 1995-11-08 | $7700.00 | Window Closed / Lapsed |